Mehdi Shakouri Khomartash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mehdi Shakouri Khomartash has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Abbas Morovvati
Department of Microbiology, Faculty of Basic Science Qom Branch, Islamic Azad University, Qom, Iran
1 shared publication - Ali Haji Esmaili Qomi
Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran
1 shared publication Ashkan Dirbazian
Department of Microbiology, Faculty of Basic Science Qom Branch, Islamic Azad University, Qom, Iran
1 shared publication- Fernando Berton Zanchi
Laboratório de Bioinformática e Química Medicinal (LABIOQUIM), Fundação Oswaldo Cruz Rondônia, Porto Velho, RO, Brazil
1 shared publication - Mahdi Ghorbani
Department of Medical Laboratory Sciences, School of Allied Medical Sciences AJA University of Medical Sciences Tehran Iran
1 shared publication - Mahtab Noorifard
Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 16 December 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (24) , e70257
Immunoinformatics approach: Developing a multi‐epitope vaccine with novel carriers targeting monkeypox virus
Since May 2022, the global spread of monkeypox virus (MPXV) has presented a significant threat to public health. Despite this, there are limited preventive measures available. In this study, different computational tools were employed to design a multi‐epitope vaccine targeting MPXV. Three key MPXV proteins, M1R, B6R, and F3L, were chosen for epitope selection, guided by bioinformatic analyses to identify immunodominant epitopes for T‐ and B‐cell activation. To enhance immune stimulation and facilitate targeted delivery of the vaccine to specific cells, the selected epitopes were linked to novel carriers, including the extracellular domain of cytotoxic T lymphocyte–associated antigen 4 (CTLA‐4), a 12‐mer Clec9a binding peptide (CBP‐12), and a Toll‐like receptor 2 (TLR2) peptide ligand. The designed vaccine construct exhibited strong antigenicity along with nonallergenic and nontoxic properties, with favorable physicochemical characteristics. The validated vaccine's tertiary structure underwent evaluation for interactions with CD80/86, Clec9a, and TLR2 through molecular docking and molecular dynamics simulation. The results ensured the vaccine's stability and high affinity for the aforementioned receptors. In silico immune simulations studies revealed robust innate and adaptive immune responses, including enhanced mucosal immunity essential for protection against MPXV. Ultimately, the DNA sequence of the vaccine construct was synthesized and successfully cloned into the pET‐22b(+) vector. Our study, through integration of computational predictions, suggests the proposed vaccine's potential efficacy in safeguarding against MPXV; however, further in vitro and in vivo validations are imperative to assess real‐world effectiveness and safety.
- 16 December 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (24) , e70257
Immunoinformatics approach: Developing a multi‐epitope vaccine with novel carriers targeting monkeypox virus
Since May 2022, the global spread of monkeypox virus (MPXV) has presented a significant threat to public health. Despite this, there are limited preventive measures available. In this study, different computational tools were employed to design a multi‐epitope vaccine targeting MPXV. Three key MPXV proteins, M1R, B6R, and F3L, were chosen for epitope selection, guided by bioinformatic analyses to identify immunodominant epitopes for T‐ and B‐cell activation. To enhance immune stimulation and facilitate targeted delivery of the vaccine to specific cells, the selected epitopes were linked to novel carriers, including the extracellular domain of cytotoxic T lymphocyte–associated antigen 4 (CTLA‐4), a 12‐mer Clec9a binding peptide (CBP‐12), and a Toll‐like receptor 2 (TLR2) peptide ligand. The designed vaccine construct exhibited strong antigenicity along with nonallergenic and nontoxic properties, with favorable physicochemical characteristics. The validated vaccine's tertiary structure underwent evaluation for interactions with CD80/86, Clec9a, and TLR2 through molecular docking and molecular dynamics simulation. The results ensured the vaccine's stability and high affinity for the aforementioned receptors. In silico immune simulations studies revealed robust innate and adaptive immune responses, including enhanced mucosal immunity essential for protection against MPXV. Ultimately, the DNA sequence of the vaccine construct was synthesized and successfully cloned into the pET‐22b(+) vector. Our study, through integration of computational predictions, suggests the proposed vaccine's potential efficacy in safeguarding against MPXV; however, further in vitro and in vivo validations are imperative to assess real‐world effectiveness and safety.
- Open Access
- 1 October 2023
- Published by Apex Publishing in Scientific Journal of Kurdistan University of Medical Sciences
- Vol. 28 (4) , 66-76
Detection of SARS-CoV-2 by Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) Technique
Background and Aim: Covid-19 disease is a global health concern that requires rapid quantitative diagnostic testing. The standard technique for diagnosing SARS-CoV-2 is now REAL-TIME PCR. The aim of this study was to design a sensitive Reverse Transcription Loop-Mediated Isothermal Amplification method for the early identification of SARS-CoV-2. Material and Methods: In ...
- 1 October 2023
- Published by Apex Publishing in Scientific Journal of Kurdistan University of Medical Sciences
- Vol. 28 (4) , 66-76
Open AccessDetection of SARS-CoV-2 by Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) Technique
Background and Aim: Covid-19 disease is a global health concern that requires rapid quantitative diagnostic testing. The standard technique for diagnosing SARS-CoV-2 is now REAL-TIME PCR. The aim of this study was to design a sensitive Reverse Transcription Loop-Mediated Isothermal Amplification method for the early identification of SARS-CoV-2. Material and Methods: In ...